Skip to content

Based on the "Yi Qi Zhou Liu" theory, observation of the clinical efficacy of gua sha combined with panlong moxibustion in the intervention of phlegm-dampness excess type essential hypertension.

Based on the "Yi Qi Zhou Liu" theory, observation of the clinical efficacy of gua sha combined with panlong moxibustion in the intervention of phlegm-dampness excess type essential hypertension.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002457
Enrollment
Unknown
Registered
2025-12-24
Start date
2022-06-01
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Phlegm-dampness Obstruction Type Essential Hypertension

Interventions

Control Group:Routine drug therapy + health education
Gua Sha Group:Adding gua sha therapy to conventional treatment
Dragon Moxibustion Group:In addition to conventional treatment, add Pánlóng Jiu therapy.
Gua Sha Combined with Panlong Moxibustion Group:Combined therapy with gua sha and panlong moxibustion on the basis of conventional treatment.

Sponsors

Hunan University of Traditional Chinese Medicine First Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with primary hypertension and identified as having phlegm-dampness stagnation syndrome according to (diaagnosis). 2. Patients with Grade 1 hypertension who did not achieve target levels after 12 weeks of lifestyle intervention and patients with Grade 2 hypertension. 3. Patients classified as low-risk, medium-risk, or high-risk based on risk stratification. 4. Patients aged 18 to 65 years, regardless of gender. 5. Patients who provided informed consent and voluntarily participated.

Exclusion criteria

Exclusion criteria: 1. Pseudohypertension/malignant hypertension and those with acute cerebrovascular disease, myocardial infarction, heart failure, or diabetic nephropathy; 2. Pregnant or breastfeeding women; 3. Skin ulceration/injury/inflammation/severe edema at the intervention site; 4. Currently participating in other clinical trials.1.

Design outcomes

Primary

MeasureTime frame
blood pressure;TCM Syndrome Score;Five lipid tests;

Secondary

MeasureTime frame
Homocysteine;Hamilton Anxiety Rating Scale;SF-36 Health Survey;

Countries

China

Contacts

Public ContactLiu Bin

Hunan University of Traditional Chinese Medicine First Affiliated Hospital

377915725@qq.com15974178746

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026